Zevra Therapeutics (NASDAQ: ZVRA) net income
Zevra Therapeutics reported a net profit of $83.2m for fiscal 2025; in fiscal 2024 it reported a net loss of $105.5m. Its net margin was 78.2%. Earnings per share were $1.40.
Fiscal 2025 is the highest of the 10 fiscal years on record for Zevra Therapeutics. It reported a loss in 9 of those 10 years.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Net income by fiscal year
| Fiscal year | Net income | Change | Net margin | Earnings per share |
|---|---|---|---|---|
| 2025 | $83.2m | — | 78.2% | $1.40 |
| 2024 | −$105.5m | — | −446.9% | −$2.28 |
| 2023 | −$46.0m | — | −167.7% | −$1.30 |
| 2022 | −$26.8m | — | −263.5% | −$0.78 |
| 2021 | −$8.6m | — | −29.9% | −$2.11 |
| 2020 | −$12.8m | — | −96.0% | −$3.21 |
| 2019 | −$24.5m | — | −191.0% | — |
| 2018 | −$56.5m | — | — | — |
| 2017 | −$43.4m | — | — | — |
| 2016 | −$16.5m | — | — | — |
The change compares each fiscal year with the one before and is not calculated when the previous year closed with a loss. Net margin is net income over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Zevra Therapeutics net income compared with its sector
By net income for its latest fiscal year, Zevra Therapeutics ranks 118th of the 501 US health care companies with a page on Celsmar. The sector median net margin is −6.2%; that of Zevra Therapeutics, 78.2%.
| Rank | Company | Net income | Net margin |
|---|---|---|---|
| 116th | Embecta | $95.4m | 8.8% |
| 117th | Keros Therapeutics | $87.0m | 35.7% |
| 118th | Zevra Therapeutics | $83.2m | 78.2% |
| 119th | ANI Pharmaceuticals | $78.3m | 8.9% |
| 120th | Sotera Health | $77.9m | 6.7% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the net income of Zevra Therapeutics
- How much did Zevra Therapeutics earn in fiscal 2025?
- Zevra Therapeutics reported a net profit of $83.2m for fiscal 2025. In fiscal 2024 it reported a net loss of $105.5m.
- What are the earnings per share of Zevra Therapeutics?
- They were $1.40 in fiscal 2025, compared with −$2.28 in fiscal 2024.
- What is the net margin of Zevra Therapeutics?
- In fiscal 2025 its net profit was 78.2% of its revenue.
- What was the most profitable year for Zevra Therapeutics?
- Of its last 10 fiscal years, fiscal 2025, with $83.2m.
- Where does Zevra Therapeutics rank in its sector by net income?
- It ranks 118th of the 501 US health care companies with a page on Celsmar, by net income for its latest fiscal year.
- Where do the figures for Zevra Therapeutics come from?
- From the annual report (Form 10-K) that Zevra Therapeutics files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Zevra Therapeutics files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018 · 2017 · 2016. More on Zevra Therapeutics: the Zevra Therapeutics page · annual accounts · revenue · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.